Zevra Therapeutics Inc. logo

Zevra Therapeutics Inc.

ZVRA | NASDAQ
Chart Builder DCF Calculator
$11.67
+$0.06 (+0.52%)
At close: Sep 21, 2026, 4:00 PM ET
$11.80
+$0.13 (+1.11%)
Pre-market: Sep 22, 2026, 7:23 AM ET

Market Data

Market Cap
$689.87M
Enterprise Value
$468.3M
Beta
0.95
Average Volume
1.57M
Shares Outstanding (Diluted)
61.34M
Shares Change YoY
8.9%
Institutional Ownership
70.74%
Exchange
NASDAQ
ISIN
US4884452065

Price Performance

Price Change 1M
-1.9%
Price Change 3M
-10.2%
Price Change 6M
27.8%
Price Change YTD
39.9%
Price Change 1Y
46.8%
Price Change 3Y
140.1%
Price Change 5Y
28.2%
1M CAGR (ann.)
0.9%
1Y CAGR (ann.)
47.0%
5Y CAGR (ann.)
5.4%
All-Time CAGR
-21.2%

Valuation

PE Ratio
12.55
Forward PE
10.51
PEG Ratio
0.01
Forward PEG
-0.78
PS Ratio
5.07
Forward PS
3.90
PB Ratio
3.17
P/FCF Ratio
17.81
P/Adj. FCF Ratio
30.67
P/OCF Ratio
20.84
EV/Sales
3.44
EV/EBIT
6.54
EV/EBITDA
6.41
EV/FCF
12.09
Earnings Yield
8.0%
FCF Yield
5.6%
Adj. FCF Yield
3.3%

Financial Health

Net Cash
$221.57M
Total Debt
$0
Cash & Short-Term Investments
$221.57M
Total Assets
$302.71M
Current Ratio
5.17
Quick Ratio
5.12
Debt / Equity Ratio
0.01
Debt / EBITDA
0.00
Debt / FCF
0.00
OCF / Debt
N/A
Interest Coverage
6.84
Altman Z-Score
5.16
Piotroski F-Score
6

Margins & Profitability

Gross Profit Margin
95.0%
Operating Profit Margin
28.7%
EBITDA Margin
53.7%
Net Profit Margin
42.8%
FCF Margin
28.5%
Adj. FCF Margin
16.5%
SBC / Revenue
9.7%
SBC Impact (per share)
-41.9%

Returns

Return on Assets
19.3%
Return on Equity
32.8%
Return on Invested Capital
12.9%
Return on Capital Employed
15.4%
Return on Tangible Assets
19.9%

Historical Growth (CAGR)

Revenue CAGR 3Y
100.7%
Revenue CAGR 5Y
36.8%
Revenue CAGR 10Y
35.4%
EPS CAGR 3Y
532.3%
EPS CAGR 5Y
89.1%
EPS CAGR 10Y
41.7%
FCF CAGR 3Y
222.4%
FCF CAGR 5Y
26.8%
FCF CAGR 10Y
14.0%

Analyst Forecasts

Analyst Rating
Buy
Analyst Count
10
EPS Growth Next 3Y
26.4%
Revenue Growth Next 3Y
25.1%
Earnings Date
Nov 3, 2026
EPS Estimate (next Q)
$0.14
EPS Growth Est (next Q)
-1500.0%
Revenue Est (next Q)
$37.08M
Revenue Growth Est (next Q)
42.3%

Fair Value Estimates

Graham Number
$8.78
Graham Upside
-24.8%
Lynch Fair Value
$23.25
Lynch Upside
99.2%
Price Target
$25.75
Price Target Upside
120.7%

Cash Flow

Operating Cash Flow
$39.54M
Free Cash Flow
$38.73M
Adj. Free Cash Flow
$22.5M
FCF Per Share
$0.55
OCF Per Share
$0.56
OCF/S Ratio
24.5%

Income Statement

Revenue
$136.07M
Gross Profit
$129.21M
Operating Income
$39.07M
EBITDA
$73.01M
Net Income
$58.26M
EPS (Diluted)
$0.93
Revenue / Employee
$2.23M
Profit / Employee
$955.13K
Employees
61

© 2026 bestshares.com. All rights reserved.